| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 SEM Herman, AL Gordon, E Hertlein, A Ramanunni, X Zhang, ... Blood, The Journal of the American Society of Hematology 117 (23), 6287-6296, 2011 | 991 | 2011 |
| NF-κB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes H Wang, E Hertlein, N Bakkar, H Sun, S Acharyya, J Wang, M Carathers, ... Molecular and cellular biology 27 (12), 4374-4387, 2007 | 294 | 2007 |
| Close association of RNA polymerase II and many transcription factors with Pol III genes D Raha, Z Wang, Z Moqtaderi, L Wu, G Zhong, M Gerstein, K Struhl, ... Proceedings of the National Academy of Sciences 107 (8), 3639-3644, 2010 | 219 | 2010 |
| ASC directs NF-κB activation by regulating receptor interacting protein-2 (RIP2) caspase-1 interactions A Sarkar, M Duncan, J Hart, E Hertlein, DC Guttridge, MD Wewers The journal of immunology 176 (8), 4979-4986, 2006 | 153 | 2006 |
| 17-DMAG targets the nuclear factor-κB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition E Hertlein, AJ Wagner, J Jones, TS Lin, KJ Maddocks, WH Towns III, ... Blood, The Journal of the American Society of Hematology 116 (1), 45-53, 2010 | 130 | 2010 |
| Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia SS Chen, A Raval, AJ Johnson, E Hertlein, TH Liu, VX Jin, MH Sherman, ... Proceedings of the National Academy of Sciences 106 (32), 13433-13438, 2009 | 107 | 2009 |
| Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma L Alinari, B Yu, BA Christian, F Yan, J Shin, R Lapalombella, E Hertlein, ... Blood, The Journal of the American Society of Hematology 117 (17), 4530-4541, 2011 | 92 | 2011 |
| TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia V Balatti, L Rizzotto, C Miller, A Palamarchuk, P Fadda, R Pandolfo, ... Proceedings of the National Academy of Sciences 112 (7), 2169-2174, 2015 | 80 | 2015 |
| Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease E Hertlein, KA Beckwith, G Lozanski, TL Chen, WH Towns, AJ Johnson, ... PloS one 8 (10), e76607, 2013 | 72 | 2013 |
| Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia K Kämpjärvi, TM Järvinen, T Heikkinen, AS Ruppert, L Senter, KW Hoag, ... Oncotarget 6 (3), 1884, 2015 | 62 | 2015 |
| Anti–BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib EM McWilliams, CR Lucas, T Chen, BK Harrington, R Wasmuth, ... Blood advances 3 (3), 447-460, 2019 | 55 | 2019 |
| RelA/p65 regulation of IκBβ E Hertlein, J Wang, KJ Ladner, N Bakkar, DC Guttridge Molecular and cellular biology 25 (12), 4956-4968, 2005 | 48 | 2005 |
| The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells SV Gupta, E Hertlein, Y Lu, EJ Sass, R Lapalombella, TL Chen, ME Davis, ... Clinical cancer research 19 (9), 2406-2419, 2013 | 46 | 2013 |
| Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells E Hertlein, G Triantafillou, EJ Sass, JD Hessler, X Zhang, D Jarjoura, ... Blood, The Journal of the American Society of Hematology 116 (14), 2554-2558, 2010 | 46 | 2010 |
| Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib CR Miller, AS Ruppert, NA Heerema, KJ Maddocks, J Labanowska, ... Blood advances 1 (19), 1584-1588, 2017 | 43 | 2017 |
| Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74+ B-cell Malignancies Y Mao, G Triantafillou, E Hertlein, W Towns, M Stefanovski, X Mo, ... Clinical Cancer Research 19 (2), 347-356, 2013 | 42 | 2013 |
| DNA origami nanostructures elicit dose‐dependent immunogenicity and are nontoxic up to high doses In vivo CR Lucas, PD Halley, AA Chowdury, BK Harrington, L Beaver, ... Small 18 (26), 2108063, 2022 | 39 | 2022 |
| Signalling to drug resistance in CLL E Hertlein, JC Byrd Best practice & research Clinical haematology 23 (1), 121-131, 2010 | 36 | 2010 |
| Leukemic B cell CTLA-4 suppresses costimulation of T cells P Do, KA Beckwith, C Cheney, M Tran, L Beaver, BG Griffin, X Mo, Y Liu, ... The Journal of Immunology 202 (9), 2806-2816, 2019 | 33 | 2019 |
| The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia CR Miller, AS Ruppert, S Fobare, TL Chen, C Liu, A Lehman, JS Blachly, ... Oncotarget 8 (16), 25942, 2017 | 29 | 2017 |
